Skip to main content

Table 5 Antimicrobial regimens for the treatment of Acinetobacter baumannii bacteremic pneumonia (inappropriate antibiotics)

From: Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia

Main agents useda,b

No. (%) of patients

(n = 185)

APACHE II score, median (IQR)d

No. (%) of patients

Combination therapye

14-Day Mortality

P-value

28-Day Mortality

P-value

Anti-pseudomonas penicillin-based therapy

28 (15.1)

33 (24–39)

3 (10.7)

19 (67.9)

.142

22 (78.6) f

.077

Anti-pseudomonas cephalosporin-based therapy

36 (19.5)

31 (21–40)

8 (22.2)

17 (47.2)

.287

22 (61.1)

.710

Carbapenem-based therapy

61 (33.0)

29 (24–38)

11 (18.0)

38 (62.3)

.170

45 (73.8)

.047

Colistin-based therapy

7 (3.8)

28 (21–30)

7 (100)

3 (42.9)

.702

6 (85.7)

.425

Tigecycline-based therapy

13 (7.0)

33 (25–39)

10 (76.9)

9 (69.2)

.390

10 (76.9)

.382

Fluoroquinolone-based therapy

10 (5.4)

28 (20–39)

3 (30.0)

5 (50.0)

.737

7 (70.0)

1

Sulbactam-based therapy

10 (5.4)

30 (18–37)

6 (60.0)

5 (50.0)

.737

7 (70.0)

1

Carbapenem + colistin-based therapy

3 (1.6)

19, 27, 28

1 (33.3)

0

.088

3 (100)

.555

Carbapenem + tigecycline-based therapy

4 (2.2)

27 (22–31)

2 (50.0)

2 (50.0)

1

3 (75.0)

1

Carbapenem + sulbactam-based therapy

5 (2.7)

31 (29–31)

3 (60.0)

3 (60.0)

1

4 (80.0)

.655

Colistin + tigecycline-based therapy

2 (1.1)

19, 40

1 (50.0)

1 (50.0)

1

2 (100)

.535

Carbapenem + colistin + tigecycline-based therapy

1 (0.5)

19

0

0

.449

1 (100)

1

Antimicrobial regimensc

 Anti-pseudomonas penicillin only

25 (13.5)

33 (24–39)

 

18 (72.0)

.068

20 (80.0)

.070

 Anti-pseudomonas cephalosporin only

28 (15.1)

32 (22–41)

 

14 (50.0)

.553

17 (60.0)

.714

 Carbapenem + colistin

2 (1.1)

27, 28

 

0

.200

2 (100.0)

.535

 Carbapenem + tigecycline

2 (1.1)

25, 33

 

1 (50.0)

1

1 (50.0)

1

 Carbapenem + sulbactam

2 (1.1)

31, 40

 

2 (100)

.503

2 (100)

.535

 Carbapenem + fluoroquinolone

1 (0.5)

43

 

1 (100)

1

1(100)

1

 Carbapenem + tigecycline + colistin

1 (0.5)

19

 

0

.449

1(100)

1

 Tigecycline only

3 (1.6)

30, 33, 38

 

3 (100)

.254

3 (100)

.555

 Colistin + tigecycline

1 (0.5)

40

 

1 (100)

1

1 (100)

1

  1. aAn antimicrobial agent (or antimicrobial agents)-based therapy denotes the corresponding antimicrobial agent(s) alone or in combination with other antimicrobial agent(s)
  2. b“Colistin” denotes intravenous colistin only. Inhaled colistin is not included
  3. cNot in combination with other antimicrobial agents
  4. dIQR, interquartile range. When the case number is less than 4, the APACHE II score for each case is shown
  5. eCombination therapy is defined as administration of more than one antimicrobial agent
  6. fPatients receiving antipseudomonal penicillin therapy had a significantly higher 28-day mortality compared to other antimicrobial therapy after multivariable adjustment
Back to article page